We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CorePharma Wants Investigation Into Endo’s Moban Withdrawal
CorePharma Wants Investigation Into Endo’s Moban Withdrawal
June 18, 2013
Seeking an avenue for a possible ANDA approval, CorePharma has petitioned the FDA to investigate whether Endo Pharmaceuticals discontinued its antipsychotic drug Moban in 2010 for reasons of safety and effectiveness, or as the generic drugmaker suspects, due to sourcing issues.